Percona Announces Line-up Of Speakers for Percona Live 2023, the World’s Largest Independent Database Conference
20.4.2023 16:00:00 EEST | Business Wire | Press release
Percona, a leader in enterprise-grade open source database software and services, will host the latest in its annual Percona Live conference series in Denver at the Marriott Tech Center from May 22-24, 2023. Percona Live is the longest-running independent open source database conference, covering a range of database and data management topics including cloud-native deployments, performance improvements, and real-world experience from some of the world’s largest database deployments.
The event will provide three days of hands-on tutorials, breakout sessions, keynote addresses, networking, and socializing with some of the world’s most experienced database professionals. Inspired by the Denver location, this year's event is themed CLIMB. The concept is about reaching peak database performance with open source databases and how Percona serves as a guide to doing so. At the event, industry experts will provide insights around some of the world's most popular databases — MySQL, PostgreSQL, and MongoDB — as well as other open source technologies such as Clickhouse, Vitess, and Kubernetes.
“Open source is essential to driving innovation, which is why we’re excited to bring back Percona Live in person following the success of last year's event in Austin,” commented Ann Schlemmer, CEO of Percona. “Over three days we will bring together the open source community to explore the latest technical advances around databases, approaches to data management and how we can deploy these tools more effectively. The conference enables the community to share their knowledge and experiences with one another to contribute to the future of open source.”
Keynote speakers at this year’s event include:
- Ann Schlemmer, CEO of Percona on The Future of Percona
-
Rachel Stephens, Senior Industry Analyst at RedMonk, As You Wish
Open source databases: a classic tale of true love and high adventure - Peter Zaitsev, Founder of Percona, Unlocking Data Freedom: Harnessing Open Source to Overcome Data Gravity
Additional topics include:
- Database Observability: Through the lens of SRE - Archana Jattigari, Credit Karma
- Why Machine Learning for Automatically Optimizing Databases Doesn't Work - Andy Pavlo, Carnegie Mellon University / OtterTune
- Operating a 120 TB MongoDB dataset on Kubernetes - David Noriega and Eric Fox, Adobe
- No Passwords, Please, We're Pinterest: Secure Identity-Based Authentication for MySQL - Ernie Souhrada, Pinterest
- Reducing Cost and Improving Performance with Data Modeling in Postgres - Charly Batista, Percona
- Upgrading to MySQL 8.0 - Michael Coburn, Percona
- What is the place of AI in SQL querying? - Tatiana Krupenya, DBeaver Corporation
- Pen-testing open source databases (MySQL and PostgreSQL) - Alexander Rubin, AWS
This year’s Percona Live is sponsored by Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver just to name a few. For more information or to register for the conference, visit: https://www.percona.com/live/conferences
About Percona
Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.
Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.
Databases run better with Percona.
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005301/en/
Contact information
Press Contacts
Annabel Lander
Onebite for Percona
percona@onebite.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom